# International Geneva Directory of Geneva Global Health Actors

The Global Antibiotic Research and Development Partnership | GARDP

## https://www.gardp.org/

15 Chemin Louis-Dunant - 1202 Geneva Tel +41 22 555 19 90 | mail: contact@gardp.org

### **BACKGROUND AND MISSION**

The Global Antibiotic Research and Development Partnership (GARDP) is a not-for-profit research and development (R&D) organization that addresses global public health needs by developing and delivering new or improved antibiotic treatments, while endeavouring to ensure their sustainable access. Initiated by the World Health Organization (WHO) and the Drugs for Neglected Disease initiative (DNDi) in May 2016, GARDP is an important element of WHO's Global Action Plan on Antimicrobial Resistance that calls for new public-private partnerships to encourage R&D of new antimicrobial agents and diagnostics. GARDP benefits from its unique parentage, drawing strength from both WHO's mandate to drive the global response to antimicrobial resistance and set health priorities, and DNDi's expertise in harnessing partnerships to build a pipeline for neglected diseases and deliver not-for-profit, needs-driven R&D. Partnerships with governments, academia, research centres and industry are at the heart of GARDP's work.

Each programme incorporates sustainable access and stewardship strategies to ensure treatments are affordable and available to all those who need them. GARDP's mission is to work in partnership with the public and private sectors to develop and deliver new treatments for bacterial infections where drug resistance is present or emerging, or for which inadequate treatment exists. In July 2018, GARDP was established as an independent Swiss Foundation and an initial board of directors appointed. Marking the end of its incubation in DNDi, GARDP and DNDi agreed to an ongoing collaboration for a period of three years. Based on their shared commitment to public health-driven R&D, DNDi and GARDP will continue to collaborate sharing specialized R&D expertise and capacity, policy advocacy expertise, and with support from DNDi's regional network for in-country implementation.

## **AREAS OF INTEREST**

- Sexually transmitted illnesses
- Neonatal sepsis and children antibiotics
- Basic and applied research
- Antimicrobial resistance

### **HEALTH-RELATED ACTIVITIES**

GARDP's work begins with prioritizing R&D to focus on unaddressed public health gaps, notably for drug-resistant bacterial infections. Through partnership, collaboration, and coordination as well as the adoption of innovative business models, GARDP will ensure that R&D investment offers public health returns, delinking the cost of antibiotic treatments from

the price of the products and volume-based sales. Significant progress to address global health priorities such as drug-resistant infections in children, newborns with sepsis, and sexually-transmitted infections was made during GARDP's final year under its incubation by DNDi. Activities included undertaking a global observational study in 11 countries, conducting two clinical trials, accelerating the development of antibiotics for children, recovering molecules for their potential value for antimicrobial drug development, and sharing the knowledge of established antimicrobial researchers and those starting their careers through REVIVE.

#### **GOVERNANCE AND STAFF**

GARDP's Board meets at least twice a year and is GARDP's ultimate policy and decision-making authority. The Board is composed of up to 15 members and includes leading international figures in global health. Current chair is Ramanan Laxminarayan. The Scientific Advisory Committee (SAC) comprises scientists with expertise in various disciplines within infectious diseases and microbiology. It has a consultative function: its members advise GARDP's Board of Directors but operates independently of the Board of Directors and GARDP's Management Team. The Board approves the selection of members. Current chair is Jutta Heim. By 2023, GARDP anticipates having 55 full time equivalent (FTE) staff, 70% of whom will be dedicated to R&D. As per February 2017, GARDP has a core staff of 10 people, with additional support from DNDi.

## **FUNDING SOURCES AND BUDGET**

The price tag to cover the costs of implementing GARDP's initial programmes over the next seven years is slated at EUR 270 million which includes support to introduce up to four treatments and bring up to four candidates to pre-clinical and clinical development. Currently, EUR 6.5 million has been secured. € 20.000.000 is the annual budget for 2018, projected to rise to 35 for 2019.

#### **PUBLICATIONS**

Publications and report are available at

https://www.gardp.org/2017/news-resources/publications-reports/

Scientific articles are at <a href="https://www.gardp.org/category/news-resources/scientific-articles/">https://www.gardp.org/category/news-resources/scientific-articles/</a>

Last update: 21.08.2019

